{"id":390301,"date":"2019-12-20T00:00:00","date_gmt":"2019-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0001-2019-biopharma-heart-failure-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-17T11:36:41","modified_gmt":"2026-04-17T11:36:41","slug":"dlsfcv0001-2019-biopharma-heart-failure-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0001-2019-biopharma-heart-failure-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Heart Failure | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>Heart failure (<abbr data-original-title=\"heart failure\" title=\"\">HF<\/abbr>) can be categorized into acute or chronic, and we focus on both settings in this report.\u00a0<abbr data-original-title=\"heart failure\" title=\"\">HF<\/abbr>\u00a0patients are subject to high rates of mortality and morbidity. While much progress has been made in the pharmacological management of\u00a0<abbr data-original-title=\"heart failure\" title=\"\">HF<\/abbr>, it is mainly in chronic\u00a0<abbr data-original-title=\"heart failure\" title=\"\">HF<\/abbr>\u00a0(<abbr data-original-title=\"chronic heart failure\" title=\"\">CHF<\/abbr>) with reduced ejection fraction (<abbr data-original-title=\"heart failure with reduced ejection fraction\" title=\"\">HFrEF<\/abbr>); a significant unmet need remains for\u00a0<abbr data-original-title=\"chronic heart failure\" title=\"\">CHF<\/abbr>with preserved ejection fraction (<abbr data-original-title=\"heart failure with preserved ejection fraction\" title=\"\">HFpEF<\/abbr>). In addition, the treatment of acute\u00a0<abbr data-original-title=\"heart failure\" title=\"\">HF<\/abbr>\u00a0(<abbr data-original-title=\"acute heart failure\" title=\"\">AHF<\/abbr>) is dominated by older, generic products. We provide insights into the continued uptake of Entresto over the 2017-2027 forecast period, and its expected launch for\u00a0<abbr data-original-title=\"heart failure with preserved ejection fraction\" title=\"\">HFpEF<\/abbr>\u00a0in 2020. We also examine the potential of several new therapies for\u00a0<abbr data-original-title=\"chronic heart failure\" title=\"\">CHF<\/abbr>\u00a0(Boehringer Ingelheim\/Eli Lilly\u2019s Jardiance, AstraZeneca\u2019s Farxiga, Lexicon Pharmaceuticals\/Sanofi\u2019s sotagliflozin, Bayer\/<abbr data-original-title=\"Merck Sharp &#038; Dohme\" title=\"\">MSD<\/abbr>\u2019s vericiguat, and Amgen\/Cytokinetics\u2019s omecamtiv mecarbil), and assess how the\u00a0<abbr data-original-title=\"acute heart failure\" title=\"\">AHF<\/abbr>\u00a0market will evolve given the lack of new drug launches.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How large is the treatable HF population and how will diagnosis rates change over time?<\/li>\n<li>What is the current state of treatment in HF? Which drugs are the most important and why? What clinical needs remain unfulfilled?<\/li>\n<li>How is the use of Entresto going to evolve over the forecast period and will it reach blockbuster status?<\/li>\n<li>How is the treatment of\u00a0<abbr data-original-title=\"heart failure with preserved ejection fraction\" title=\"\">HFpEF<\/abbr>\u00a0going to evolve following the launches of the first evidence-based drugs for this population?<\/li>\n<li>For which emerging therapies do thought leaders express the most enthusiasm? What level of market penetration can we expect of new therapies given the increasingly crowded and competitive landscape?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390301","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-heart-failure","biopharma-therapy-areas-heart-failure","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390301\/revisions"}],"predecessor-version":[{"id":576558,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390301\/revisions\/576558"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}